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Dear Editors
Sibutramine was withdrawn from the market in Europe, USA, 
Canada, Australia, and other countries due to a large-scale, 
long-term study (SCOUT: Sibutramine Cardiovascular Outcome 
Trial), which demonstrated an increased risk of heart attack 
and stroke in obese patients with type-2 diabetes and/or higher 
cardiovascular risk. While recognizing that sibutramine should 
be excluded from use in patients with pre-existing cardiovas-
cular disease1, the study sponsor (Abbott laboratories) and 
some of its researchers argue that a sub-population of patients 
could benefit from the weight loss effect of sibutramine.1,2 
Along this line, Coutinho and James2 commented that SCOUT 
studied a population remarkably different from patients that 
use sibutramine in daily life and that most participants did not 
meet treatment criteria specified in the drug label. The au-
thors also stated that “benefits of weight loss” were dismissed 
by FDA and EMA as an efficacy criterion and that risk-benefit 
balance was apparently biased by the idea that “too many 
individuals would be using the medication merely for cosmetic 
reasons”.2 The aforementioned interpretation is at odds with 
conclusions reached by the American (FDA) and European (EMA) 
agencies and the Advisory Committee on Medicines (CATEME) 
of the Brazilian agency (ANVISA). After an extensive analysis of 
available data on the safety and efficacy of sibutramine, FDA, 
EMA, and CATEME found no scientific basis for adopting a risk 
mitigation strategy. First, because SCOUT data, given the over-
lap in patients with obesity, diabetes, and cardiovascular risk, 
did not reveal any point or subpopulation of patients where 
the benefit of weight loss in cardiovascular morbidity would 
exceed the risk arising from the intrinsic cardiovascular effect 
of the drug (e.g., a small but sustained rise in blood pres-
sure and heart rate). Second, because no study has defined a 
population of patients who may benefit from sibutramine; i.e, 
a group for whom the benefits clearly outweigh the risks. The 
SCOUT showed that, while causing some weight reduction, 
sibutramine increased cardiovascular morbidity in patients 
with type-2 diabetes and or a higher cardiovascular risk. It is 
obvious that SCOUT participants were a subgroup of patients at 
higher risk for heart attacks and strokes. Nonetheless, it is also 
clear that sibutramine-caused weight loss did not prevent or 
ameliorate cardiovascular morbidity in this group of patients. 
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If not motivated by cosmetic purposes, treatment of obesity 
is intended to reduce morbidity and mortality associated with 
overweight, and not to decrease body weight only. So far, the 
efficacy of anorexic drugs and sibutramine has been evaluated 
only by weight loss and surrogate and/or other intermediate 
efficacy outcomes. It is believed that even modest weight 
losses reached with dieting and exercises have a positive health 
impact. Weight losses obtained with anorexic drugs, however, 
do not necessarily translate into attenuation of morbidity as-
sociated with overweight. There is no clinical trial showing that 
weight loss produced by sibutramine or any other anorexic drug 
results in long-term health benefits. If it is stated that sibutra-
mine could be beneficial for some patients, this subpopulation 
has to be defined in scientifically-acceptable studies before a 
risk mitigation strategy is adopted.   
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